DNA encoded compounds
novel drug/target complex structures for FBDD/SBDD
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.
For media inquiries: email@example.com
For investor inquiries: firstname.lastname@example.org
For business development: email@example.com
OpenDEL™ is a self-service DNA-encoded library kit that enables users to explore DEL selection campaigns without revealing target identity and to experiment with DEL technology in your own laboratory. By following the manual and operating instructions, users can utilize OpenDEL™ to conduct affinity screening experiments against protein targets in their own laboratories
Don't miss out on this incredible offer!